Asklepios BioPharmaceutical has entered into a non-exclusive cross-license biotech deals agreement with Genzyme, a big pharma company.
As part of the biotech deals, Genzyme will receive rights to AskBio’s Duplex gene therapy vector technology for its internal product development and external sublicensing.
The Duplex vectors have been shown to bypass an intracellular-synthesis step necessary for converting a single-stranded DNA genome into a double-stranded genome.
This advancement results in faster onset and higher levels of gene expression.
Genzyme plans to use the Duplex vector technology, from the biotech deals, for its internal product development research.
Additionally under this biotech deals agreement, AskBio receives rights to Genzyme’s Intra-Strand Base-Pairing technology, which also supports packaging of DNA double-stranded genomes within an AAV-based gene therapy vector.
Report: Partnering Deals and Alliances with Genzyme
Report: Partnering Deals and Alliances with Sanofi
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity